KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Gains from Investment Securities: 2011-2024

Historic Gains from Investment Securities for TherapeuticsMD (TXMD) over the last 14 years, with Dec 2024 value amounting to $57,000.

  • TherapeuticsMD's Gains from Investment Securities fell 17.74% to $51,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $51,000, marking a year-over-year decrease of 17.74%. This contributed to the annual value of $57,000 for FY2024, which is 65.03% down from last year.
  • As of FY2024, TherapeuticsMD's Gains from Investment Securities stood at $57,000, which was down 65.03% from $163,000 recorded in FY2023.
  • TherapeuticsMD's 5-year Gains from Investment Securities high stood at $23.8 million for FY2020, and its period low was $57,000 during FY2024.
  • In the last 3 years, TherapeuticsMD's Gains from Investment Securities had a median value of $163,000 in 2023 and averaged $130,667.
  • Data for TherapeuticsMD's Gains from Investment Securities shows a maximum YoY tumbled of 98.52% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows TherapeuticsMD's Gains from Investment Securities stood at $23.8 million in 2020, then plummeted by 98.52% to $353,000 in 2021, then tumbled by 51.27% to $172,000 in 2022, then declined by 5.23% to $163,000 in 2023, then plummeted by 65.03% to $57,000 in 2024.